

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: U.S. Patent Application of Ezio GHIGO *et al.*

Serial No.: 10/595,485 Group Art Unit: 1646

Filed: September 6, 2007 Examiner: Gyan CHANDRA

Title: USE OF GHRELIN AND UNACYLATED GHRELIN COMPOSITIONS
IN INSULIN-RELATED DISEASE CONDITIONS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Supplemental to the Information Disclosure Statements filed on September 19, 2007 and January 12, 2009, this Information Disclosure Statement is being filed in the manner prescribed by 37 CFR 1.97(b) - (d) to satisfy the duty under 37 CFR 1.56 to disclose to the Office information, known to individuals associated with the filing and prosecution of the subject application, which is material to the examination of the application.

In accordance with 37 CFR 1.97(g) and (h), this statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 CFR 1.56(b).

This Information Disclosure Statement is being filed before the earlier of the mailing date of either a final action under 37 CFR 1.113 or a notice of allowance under 37 CFR 1.311 and, under 37 CFR 1.97(c)(1), is accompanied by the following statement:

In accordance with 37 CFR 1.97(e)(2), I hereby certify that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Applicant therefore respectfully requests consideration of this Information Disclosure Statement under 37 CFR 1.97(b), 37 CFR 1.97(c), or 37 CFR 1.97(d), as appropriate.

In compliance with 37 CFR 1.98(a)(1), a list of all patents, publications, applications, or other information submitted for consideration by the Office is hereby provided by way of the attached Form PTO/SB/08.

In compliance with 37 CFR 1.98(a)(2), also enclosed is a legible copy of:

- i) each foreign patent document;
- ii) each publication or that portion which caused it to be listed;
- iii) for each cited pending unpublished U.S. patent application, the application specification including the claims, and any drawings of the application, or that portion of the application which caused it to be listed including any claims directed to that portion; and
- iv) all other information or that portion which caused it to be listed, excluding any copies of a United States patent or patent application.

It is respectfully requested that the information be expressly considered by the Examiner and that the references be made of record and appear among the "References Cited" on any patent to issue therefrom.

The Patent Office is hereby authorized to charge any deficiency, or credit any overpayment in fees to Deposit Account Number 08-0219.

Respectfully submitted,

Dated: May 28, 2009

/Hollie Baker/
Hollie L. Baker
Reg. No. 31,321
Attorney for Applicant(s)

Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
U.S.A.

Telephone: (617) 526-6000
Facsimile: (617) 526-5000

Enclosures: Form PTO/SB/08
All references listed on Form PTO/SB/08 (except US patents / applications)